Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1995-07-18
1998-05-05
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
514777, 514778, 424466, 424 44, A61K 920, A61K 946, C07C 9122, C07C 9306
Patent
active
057470685
ABSTRACT:
Pharmaceutical formulations of fluoxetine or an acid addition salt thereof, suitable for manufacturing dispersible tablets by direct compression and comprising, in addition to the active ingredient, the appropriate excipients and coadjuvants, selected from among disintegrants, diluents, lubricants, anti-adherents, sweeteners, flavorings and, optionally, colorants.
Said formulations are suitable for manufacturing dispersible tablets which disintegrate in less than three minutes in water at 19.degree. C.-21.degree. C., and are appropriate for treatment of depression.
REFERENCES:
patent: 3034911 (1962-05-01), McKee et al.
patent: 3091574 (1963-05-01), Coletta et al.
patent: 3424842 (1969-01-01), Nurnberg
patent: 3622677 (1971-11-01), Short et al.
patent: 3679794 (1972-07-01), Bentholm et al.
patent: 3725556 (1973-04-01), Hanssen et al.
patent: 3852421 (1974-12-01), Koyanagi et al.
patent: 4061747 (1977-12-01), Eriksoo et al.
patent: 4194009 (1980-03-01), Molloy et al.
patent: 4314081 (1982-02-01), Molloy et al.
patent: 4666703 (1987-05-01), Kupf
patent: 4886669 (1989-12-01), Ventouras
patent: 5420156 (1995-05-01), Harfenist et al.
patent: 5464632 (1995-11-01), Cousin et al.
British Pharmacopoeia, 1993, vol. II.
Boone David E.
Lilly S. A.
Rose Shep K.
Titus Robert D.
LandOfFree
Flouxetine pharmaceutical formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Flouxetine pharmaceutical formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Flouxetine pharmaceutical formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-51296